Evolus Inc (EOLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Evolus Inc Stock (EOLS) Company Profile

Healthcare (1169)

(949) 284-4555

520 NEWPORT CENTER DRIVE, NEWPORT BEACH

@evolusaesthetic

Nächster Verdiensttermin

Neueste SEC-Einreichungen

EOLS's Discussions on Twitter

Vergleichen Sie EOLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EOLS Evolus Inc	13.99	885.87M	202.09M	-61.69M	-35.64M	-1.08
ZTS Zoetis Inc	160.46	71.85B	9.26B	2.49B	2.30B	5.47
HLN Haleon Plc Adr	10.08	45.58B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	14.06	44.58B	30.25B	1.37B	5.08B	0.4257
TEVA Teva Pharmaceutical Industries Ltd Adr	16.74	19.18B	16.54B	-1.64B	749.00M	-1.45
ITCI Intra Cellular Therapies Inc	128.60	13.67B	612.78M	-86.37M	-62.91M	-0.87

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-29	Hochstufung	Barclays	Equal Weight → Overweight
2022-06-23	Eingeleitet	Needham	Buy
2022-05-12	Hochstufung	Barclays	Underweight → Equal Weight
2022-01-20	Hochstufung	Truist	Hold → Buy
2021-05-06	Hochstufung	Mizuho	Neutral → Buy
2021-04-08	Bestätigt	H.C. Wainwright	Buy
2021-02-24	Herabstufung	Truist	Buy → Hold
2020-07-07	Herabstufung	Mizuho	Buy → Neutral
2020-02-06	Fortgesetzt	Mizuho	Buy
2019-11-26	Eingeleitet	SVB Leerink	Outperform
2019-09-05	Fortgesetzt	Mizuho	Buy
2019-06-28	Eingeleitet	Wells Fargo	Market Perform
2019-06-11	Eingeleitet	Barclays	Underweight
2019-03-20	Eingeleitet	SunTrust	Buy
2019-02-14	Eingeleitet	H.C. Wainwright	Buy
2019-01-29	Eingeleitet	Stifel	Buy

Alle ansehen

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Finanzdaten der Evolus Inc-Aktie (EOLS)

Evolus Inc (EOLS)

Evolus Inc Stock (EOLS) Company Profile

Vergleichen Sie EOLS mit anderen Aktien

Evolus Inc Stock (EOLS) Upgrades & Downgrades

Evolus Inc Aktie (EOLS) Neueste Nachrichten

Rice Hall James & Associates LLC Acquires 43,381 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit - BioSpace

Inside Evolus's Growth Strategy: CEO Takes Center Stage at Elite Beauty Summit - StockTitan

Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 - BioSpace

Evolus Sets Date for Key 2024 Financial Results: What the Beauty Industry is Watching - StockTitan

Evolus (NASDAQ:EOLS) Receives Buy Rating from HC Wainwright - MarketBeat

Legato Capital Management LLC Sells 43,769 Shares of Evolus, Inc. (NASDAQ:EOLS) - MarketBeat

Evolus (NASDAQ:EOLS) Trading 15.3% HigherTime to Buy? - MarketBeat

Evolus's SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Australia

Merck KGaA bids for SpringWorks (SWTX), Evolus (EOLS) receives FDA nod & Prothena (PRTA) struggles - substack.com

Evolus's SWOT analysis: FDA nod for filler boosts stock outlook - MSN

Evolus’s SWOT analysis: FDA nod for filler boosts stock outlook By Investing.com - Investing.com Nigeria

(EOLS) Technical Data - Stock Traders Daily

Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? - MSN

FDA approves two hyaluronic acid fillers for nasolabial folds - Healio

FDA Approves Two New Hyaluronic Acid Dermal Fillers - Medical Dialogues

Breaking Down Evolus: 4 Analysts Share Their Views - Benzinga

A great week that adds to Evolus, Inc.'s (NASDAQ:EOLS) one-year returns, institutional investors who own 70% must be happy - Simply Wall St

Sector Update: Health Care -February 13, 2025 at 03:38 pm EST - Marketscreener.com

Evolus Gets US FDA Approval for Injectable Hyaluronic Acid Gels -February 13, 2025 at 02:11 pm EST - Marketscreener.com

US FDA approves Evolus' anti-wrinkle gels - TradingView

US FDA approves Evolus' anti-wrinkle gels -February 13, 2025 at 02:02 pm EST - Marketscreener.com

Evolus, Inc. Announces FDA Approval of Evolysse?? Form and Evolysse?? Smooth Injectable Hyaluronic Acid Gels - Marketscreener.com

Game-Changing FDA Approval: Evolus Unveils Next-Gen Dermal Fillers That Outperform Restylane - StockTitan

With 70% ownership, Evolus, Inc. (NASDAQ:EOLS) boasts of strong institutional backing - Yahoo Finance

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 - BioSpace

Evolus (NASDAQ:EOLS) Trading Down 6.5%Here's Why - MarketBeat

Unlocking Beauty: Evolus Sparks Excitement with New Stock Awards for Employees! - Mi Valle

Acelyrin (NASDAQ:SLRN) versus Evolus (NASDAQ:EOLS) Financial Contrast - Defense World

Unlocking Beauty: Evolus Rewards New Talent with Stock Options and RSUs - Trabajo News

Evolus Unleashes Major Talent Expansion: 34 New Hires Secure Equity Stakes in Growth Push - StockTitan

BlackRock, Inc. Expands Stake in Evolus Inc with Strategic Acqui - GuruFocus.com

How the (EOLS) price action is used to our Advantage - Stock Traders Daily

Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World

Barclays Issues Positive Forecast for Evolus (NASDAQ:EOLS) Stock Price - Defense World

Global Jeuveau Market Insights 2025: Key Trends, Market Size, and Growth Forecast - EIN News

Barclays Raises Evolus (NASDAQ:EOLS) Price Target to $22.00 - MarketBeat

Stifel maintains Buy on Evolus, price target steady at $25 - MSN

HC Wainwright Issues Optimistic Outlook for Evolus Earnings - Defense World

Midday Stock Roundup: Virgin Galactic down 2.3% and 87% YoY - Orange County Business Journal

FY2029 Earnings Estimate for Evolus Issued By HC Wainwright - MarketBeat

HC Wainwright Weighs in on Evolus' Q4 Earnings (NASDAQ:EOLS) - MarketBeat

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? - MSN

Evolus, Inc. (NASDAQ:EOLS) Soars 30% But It's A Story Of Risk Vs Reward - Simply Wall St

HC Wainwright Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS) - MarketBeat

4 Analysts Have This To Say About Evolus - Benzinga

Evolus projects robust 2025 growth with upcoming product launches By Investing.com - Investing.com Australia

Finanzdaten der Evolus Inc-Aktie (EOLS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie EOLS